Other Pulmonary fibrosis drug developer Avalyn files IPO PharmaphorumAvalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.OtherRespiratoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies. OtherRespiratoryRead full story Post navigation Previous: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinicNext: Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
